Engineered TSC2

US11639508B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• David Kass · New York, US
• Mark J. Ranek · Baltimore, US
• Kristen Kokkonen · Baltimore, US
• Jonathan Powell · Baltimore, US
• Chirag Patel · Baltimore, US

Key dates

• Filing date: Jul 13, 2018
• Grant date: May 2, 2023
• Expiry date: Mar 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are engineered TSC2 polypeptides, and nucleic acid sequences encoding them, in which the ability of a serine residue to be phosphorylated is altered. In some aspects, the TSC2 serine residue cannot be phosphorylated (e.g., by substituting the serine residue with an alanine residue). In some aspects, the TSC2 serine acts as if it is constitutively phosphorylated (e.g., by substituting the serine residue with a glutamic acid residue). Also provided herein are engineered immune cells comprising altered TSC2 polypeptides or nucleic acid sequences encoding them, and methods of making and using such engineered immune cells.